Seagen. has filed a patent for methods of detecting, characterizing, and targeting myeloid-derived suppressor cells (MDSCs). The patent includes the use of glycan-interacting antibodies, such as anti-STn antibodies, for targeting MDSCs. The methods also involve identifying subjects who can benefit from treatment with glycan-interacting antibodies. GlobalData’s report on Seagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Seagen, Nanoparticle drug conjugates was a key innovation area identified from patents. Seagen's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Detection and targeting of myeloid-derived suppressor cells using glycan-interacting antibodies
A recently filed patent (Publication Number: US20230312747A1) describes methods for targeting and treating Myeloid-Derived Suppressor Cells (MDSCs) using glycan-interacting antibodies. MDSCs are a type of immune cell that can suppress the immune response, and they are often found in tumors.
Claim 1 of the patent describes a method of targeting MDSCs by contacting a subject or subject sample with a glycan-interacting antibody. This antibody specifically binds to a glycan called STn, which is present on MDSCs.
Claim 10 of the patent describes a method of treating a subject by administering an anti-STn antibody. This method is particularly useful for subjects who have at least one tumor that contains MDSCs.
Claim 13 specifies that the anti-STn antibody used in the treatment method is an IgG antibody. Claim 14 describes an alternative form of the antibody, which is an antibody-drug conjugate (ADC).
Claim 15 provides further details on the ADC, stating that it can contain various conjugates such as auristatin, maytansine, tubulysin, vinca alkaloid, pyrrolobenzodiazepine dimer, camptothecin, duocarmycin, amanitin, phosphoinositide 3-kinase (PI3K) inhibitor, and mitogen-activated protein kinase kinase (MEK) inhibitor.
Claim 16 explains that the ADC can be connected to the anti-STn antibody using one or more polymers. Claim 17 lists several examples of polymers that can be used, including poly(ethylene glycol) (PEG), poly(N-(2-hydroxypropyl)methacrylamide) (polyHPMA), and various carbohydrate polymers.
Claim 24 describes a method of identifying candidates for anti-STn antibody treatment. This method involves obtaining a sample from a subject, identifying MDSCs in the sample, and evaluating the MDSCs for STn expression using an anti-STn antibody. The sample can be a tumor sample or a fluid sample such as blood, plasma, lymph, saliva, or interstitial fluid.
Overall, this patent provides methods for targeting and treating MDSCs using glycan-interacting antibodies, particularly those that bind to STn. These methods have potential applications in cancer treatment and could help identify suitable candidates for anti-STn antibody therapy.
To know more about GlobalData’s detailed insights on Seagen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
